Impact of pharmacy services on time to elexacaftor-tezacaftor-ivacaftor initiation

BACKGROUND: The approval of elexacaftor-tezacaftor-ivacaftor (ELX/TEZ/IVA) expanded highly effective cystic fibrosis transmembrane receptor modulator therapy to approximately 90% of persons aged 12 years and older with cystic fibrosis. Clinical pharmacists and pharmacy technicians played a key role...

Descripción completa

Detalles Bibliográficos
Autores principales: Roder, Lauren, Simonsen, Michelle, Fitzpatrick, Lindsey, He, Jianghua, Loucks, Jennifer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10373017/
https://www.ncbi.nlm.nih.gov/pubmed/36001103
http://dx.doi.org/10.18553/jmcp.2022.28.9.989

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10373017/
https://www.ncbi.nlm.nih.gov/pubmed/36001103
http://dx.doi.org/10.18553/jmcp.2022.28.9.989

Ejemplares similares